CVC, others explore sale of drugmaker Alvogen: Bloomberg

(Reuters) - CVC Capital Partners [CVC.UL] and other private equity owners are exploring options for generic drugmaker Alvogen, including a sale, which could be valued at about $4 billion, Bloomberg reported on Tuesday.